Overall, our data shows that a KIT and MEK inhibitor combination has distinct advantages over treatments with KIT inhibitors alone in killing GIST cells and triple combination with addition of a PI3K inhibitor is even better. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.